← All trials
NCT05644301
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- Sep 30, 2026
- Completion date
- Sep 30, 2026
- First posted
- Dec 9, 2022
- Last posted
- Dec 9, 2022
- Enrollment
- 240
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of AntwerpLead sponsor
- Katholieke Universiteit LeuvenCollaborator
- Free University of AmsterdamCollaborator
- Free University of BrusselsCollaborator
- Government of BelgiumCollaborator
- University of AntwerpReponsible party - principal investigator
- University of AntwerpSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.